Estradiol (menopause)
The main estrogen, given as a patch, gel or pill (or vaginal cream, tablet or ring) to ease menopause symptoms.
FDA-approved as a patch, gel, spray, pill and vaginal product for menopause symptoms and bone loss prevention.
Used for
- Hot flashes and night sweats
- Vaginal dryness and urinary symptoms (vaginal estrogen)
- Preventing bone loss after menopause
- Sleep and mood changes around menopause
How it works
Replaces the estradiol the ovaries stop making. It acts on estrogen receptors in the brain’s temperature control, the vagina and urinary tract, and bone. Vaginal products work mostly where they are placed, with little reaching the blood.
Half-life: oral about 13–20 hours; a patch holds steady levels for 3–7 days
What the research shows
- The Women’s Health Initiative (16,608 women, oral conjugated estrogens plus a synthetic progestin) found more breast cancer, strokes, clots and heart disease. Most of the women were over 60 or more than 10 years past menopause when they started.
- Later analyses and the 2022 Menopause Society statement say the balance is better for women under 60 or within 10 years of menopause, who have the most to gain for hot flashes and bone.
- In the French ESTHER study, oral estrogen was linked to a higher risk of clots in the veins, while skin patches and gels were not. This is observational data.
- The Menopause Society advises the lowest dose that works for the shortest time needed, with yearly review, and says vaginal estrogen alone is safe to use longer for local symptoms.
Dosing
Dosing isn’t listed on the public site. In the app, each published option is shown with its source (a drug label, a clinical guideline, a trial or community reports) and can be turned into a protocol you review.
Work out the units to draw for your vial →Side effects
- Breast tenderness
- Nausea, headache
- Bloating, fluid retention
- Spotting or irregular bleeding
- Mood changes
Cautions
- A woman with a uterus needs a progestogen as well (see Progesterone): estrogen alone raises the risk of endometrial cancer.
- Not for anyone with a history of breast or other estrogen-sensitive cancer, blood clots, stroke or heart attack, active liver disease, or unexplained vaginal bleeding.
- The guideline favors starting under age 60 or within 10 years of menopause; the balance is less favorable later.
- Smoking raises the clot and stroke risk. Skin products carry less clot risk than pills in observational data.
- Needs a yearly review with a clinician, including breast screening.
Storage
Unmixed or unopened: Patches at room temperature (20–25 °C), in the pouch until applying.
From the Estradiol transdermal system label.
Interactions
CYP3A4 inducers (St. John’s wort, phenobarbital, carbamazepine, rifampin) can lower estrogen levels; inhibitors (erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, grapefruit juice) can raise them.
Not a full list. Tell your doctor and pharmacist everything you take.
More in Hormones
Reference only, not medical advice. Written for this app from the cited research. Doses marked community-reported are not from trials.